Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1

Conditions

Ovarian Neoplasms 52Fallopian Tube Neoplasms 48Endometrial Neoplasms 17Uterine Cervical Neoplasms 16Carcinoma, Ovarian Epithelial 15Brenner Tumor 15Carcinoma, Non-Small-Cell Lung 7Breast Neoplasms 7Esophageal Neoplasms 6Pancreatic Neoplasms 5Neoplasm Metastasis 5Endometrial Adenocarcinoma 5Stomach Neoplasms 4Melanoma 4Lung Neoplasms 4Triple Negative Breast Neoplasms 3Testicular Neoplasms 3Prostatic Neoplasms 3Peritoneal Neoplasms 3Neoplasms 3Carcinoma, Renal Cell 3Uterine Neoplasms 2Urinary Bladder Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Sarcoma 2Salivary Gland Neoplasms 2Recurrence 2Platinum-Refractory Fallopian Tube Carcinoma 2Ovarian Germ Cell Cancer 2

Interventions

olaparib 1liposomal doxorubicin 1durvalumab 1cediranib 1Topotecan 1Taxes 1Specimen Handling 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Doxorubicin 1Disulfides 1Contrast Media 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Fallopian Tube Mucinous Adenocarcinoma × Taxes × Gynecologic × Clear all
NCT04739800 2026-05-29

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

National Cancer Institute (NCI)

Phase 2 Active not recruiting
120 enrolled 19 charts
GenitourinaryGynecologic

Fallopian Tube Mucinous Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡